Competition

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Competitive Bottom Line

Sagility owns a real but narrow moat: the only listed pure-play in U.S. healthcare payer BPM after Capgemini took WNS private in October 2025, with the highest operating margin in the listed peer set despite the smallest revenue base. The moat sits in three reinforcing layers — multi-decade payer contracts (one 25-year relationship; top-5 average tenure 18 years), NelsonHall NEAT 2026 Leader designation in Healthcare Payer Agility & Innovation, and an INR cost base wrapped in HIPAA-grade compliance — durable as long as the work stays regulated, clinical, and non-discretionary. The competitor that matters most over the next 24 months is Capgemini-WNS: the combined entity bundles a BPM book Sagility competes with against an IT-modernisation arm Sagility cannot match. The moat weakens — but does not break — at the routine voice/claims end where GenAI compresses per-transaction prices and private peers (Omega, GeBBS, IKS, AGS) win mid-market deals on price.

The Right Peer Set

The peer universe is anchored on the NelsonHall NEAT 2026 Healthcare Payer Agility & Innovation evaluation — the only published analyst grid that places Sagility in competitive context — narrowed to listed pure-plays and BPM majors with named healthcare verticals, excluding broad IT-services firms where healthcare is under 15% of revenue. Five primary peers plus one supplementary (Conduent) cover the economic shapes that matter: pure-play healthcare arbitrage (Sagility, WNS pre-deal), BPM majors with healthcare slices (EXLS, G, CNXC), the India-listed valuation anchor (FSL), and the declining U.S. legacy BPS (CNDT).

Excluded from the peer set: Cognizant (TriZetto is ~30% of revenue but is dominated by financial-services IT), Wipro / Infosys / TCS / HCLTech / Atos / DXC (healthcare BPM is <5% of revenue; they only compete on transformation-led platform bids), R1 RCM (taken private 2024; no public comp), Omega / GeBBS / AGS / IKS Health (private pure-plays — best economic comps but no listed valuation).

Notes: Sagility market cap and EV converted at ₹1 = $0.01053 (06-Jun-2026); FSL EV unavailable on a single primary source within the data window; WNS values reflect the Capgemini transaction price (US$3.3 bn EV, closed 17-Oct-2025), as live trading data ceased. CNXC P/E n/m due to FY25 loss; CNDT and WNS n/m for the same reason. Sources: peer_valuations.json, screener.in/FSL, FY25/FY26 10-Ks for U.S. peers, FY26 Sagility Q4 deck.

Takeaway: focus and margin move together. Every peer to the left of Sagility runs a lower margin because the mix is wrong; the two peers with the highest healthcare share but a different mix (CNXC at voice CX, CNDT at government Medicaid) actually lose money.

Where The Company Wins

Four advantages stand up to evidence rather than slogan.

1. The only listed pure-play after the WNS exit. NelsonHall NEAT 2026 names eleven vendors in Healthcare Payer Agility & Innovation; after WNS delisted on 17-Oct-2025, Sagility is the only listed name in that grid that is 100% U.S. healthcare. Any global allocator wanting clean, mark-to-market exposure to U.S. healthcare BPM has exactly one ticker. Evidence: NelsonHall NEAT 2026; Capgemini press release 21-Jul-2025; SEC Form 15-12G filed 27-Oct-2025 by WNS.

2. Highest operating margin in the listed cohort. Sagility runs 24.5% FY26 operating margin against a 14-16% band for Genpact, EXLS, Firstsource and pre-deal WNS, and against outright losses at CNXC and CNDT. The gap is not delivery efficiency — every Indian-listed peer runs the same arbitrage — it is the absence of low-margin voice/CX and the presence of clinical, payment-integrity, risk-adjustment and Star-ratings work the rest of the cohort cannot match in volume. Evidence: FY26 Sagility Q4 deck (adj EBITDA 25.3%); FY25 10-K filings for G, EXLS, CNXC, CNDT.

3. Embedded 18-year average tenure with the U.S. top-3 payers. Sagility serves six of the top-ten U.S. health insurers; top-5 average tenure is 18 years; one named relationship crossed 25 years (FY25 AR). Top-3 wallet share fell from 72.4% (FY23) to 59.9% (FY26) while the top-3 grew at a 9.1% CC CAGR — clients growing and concentration falling is the hardest moat signal to fake. Evidence: FY26 Q4 deck KPI table; FY25 AR p.288-349 ("25 Years with a Top U.S. Payer").

4. INR cost base inside a HIPAA-grade workflow. ~65-72% of Sagility's cost stack is people, dominantly INR-paid; revenue is dominantly USD. The same arbitrage exists at FSL — but FSL runs 16% operating margin because only ~32% of its book is healthcare and it carries BFS contact-centre work. The arbitrage is only valuable where the workflow cannot be commoditised; HIPAA + state DOI licensing + URAC/HITRUST certification make the surrounding regulatory wrapper the actual moat. Evidence: FY26 cost stack disclosure; Sagility AR FY25 "Multi-shore delivery" section.

Where Competitors Are Better

Four real gaps, each named by the competitor that exposes it.

1. Scale-led AI platform R&D — Genpact and EXLS. Genpact spent ~$170 mn on technology R&D in FY25 on a $5.1 bn revenue base; EXLS deploys EXL Code, EXL Insurance LLM and an EXL Health Genome platform on $2.1 bn revenue. Sagility's SmarTec, Synchrony and BirchAI assets are real (BirchAI acquired Mar-24) and have NelsonHall/Everest validation, but absolute R&D dollars are smaller. On the largest payer-transformation deals — where vendor selection now requires a proprietary GenAI platform commitment — Sagility is the specialist sub-bidder, not the prime.

2. The Capgemini-WNS combined offer. Capgemini paid ~$3.3 bn for WNS (closed Oct-2025) explicitly to combine intelligent operations with end-to-end IT modernisation. The combined entity can bid a single proposal covering payer core-admin platform modernisation, WNS's healthcare BPM book, and Capgemini's existing payer consulting practice. Sagility cannot match the IT-services arm; on any deal where the customer wants one throat to choke for both platform replacement and operations, Sagility is structurally disadvantaged. Risk concentrates in 2026-27 as go-to-market integration completes.

3. Provider RCM sub-scale — vs Firstsource and private peers. Sagility's provider book is ~10% of revenue (~$77 mn FY26). Firstsource runs a larger provider-RCM stack within its ~$1,019 mn healthcare-tilted book. Private peers (Omega Healthcare, IKS Health, AGS Health, GeBBS) are pure-play provider RCM and the natural choice for hospital systems that want a specialist vendor. The Devlin (Apr-23) and BroadPath (Jan-25) deals grew the RCM book, but the provider mix is small enough that the business is best understood as payer-led with an attached RCM option.

4. Diversified BPM downturn resilience — Genpact and EXLS. When U.S. payer profitability compresses (as in 2024-25 with MLR ratios spiking at Centene, Humana, Elevance), Sagility's revenue stays anchored to claim volume — but pricing renegotiations are concentrated. Genpact and EXLS spread the risk across BFSI, telecoms and analytics verticals; a 5% per-transaction price-down on healthcare claims hits Sagility's margin harder than a diversified BPM's. Cycle resilience at the operating-margin line is structurally lower.

Takeaway: Sagility's two genuine 5s are pure-play focus and operating margin; its two genuine 1s are IT modernisation and government Medicaid. The Capgemini-WNS combination is the only peer that scores 5 across both AI platform R&D and IT modernisation bundle.

Threat Map

Moat Watchpoints

Five signals tell an investor faster than headline revenue whether the moat is widening, holding, or eroding — all measurable in Sagility's quarterly KPI table or in named peer filings.